

PROFESSOR ALAN J THOMPSON FMedSci, FRCP, FRCPI FAAN FANA

PRESENT APPOINTMENTS

Dean, Faculty of Brain Sciences, University College London	2011 to date
Garfield Weston Professor of Clinical Neurology and Neurorehabilitation, UCL Institute Of Neurology, Queen Square	1998 to date
Chair, Neuroscience Academic Medical Centre, UCLP Academic Health Sci Centre	2014 to date
Consultant Neurologist, National Hospital for Neurology and Neurosurgery	1990 to date
NIHR Senior Investigator Emeritus	2016 to date

QUALIFICATIONS

MB BCH BAO BA (1979);
MD (1985; Trinity College Dublin);
FRCP (1994); FRCPI (1995); FAAN (2009); FANA (2013); FMedSci (2015)

SOME PAST APPOINTMENTS

NIHR Senior Investigator, faculty member	2008-2016
Divisional Clinical Lead for Nervous System Disorders, CLRN Central and East London	2008-2014
Programme Director, Neurological Disorders Theme, UCL Partners, AHSC	2009-2013
Programme Director, Neuroscience Programme, UCLH/UCL NIHR BRC	2012
Director, Institute of Neurology, University College London	2008 -2011
Chair, Neuroscience Domain, UCL SLMS	2010-2011
Vice-Dean and Deputy Head of Faculty of Biomedical Sciences, UCL	2009-2011
Head of Department of Brain Repair and Rehabilitation, UCL Institute of Neurology	2006-2008
Clinical Director, Neurosciences, NHNN	2003-2007

SOME PRIZES, AWARDS AND OTHER HONOURS

Recipient of Lifetime Achievement Award from Centres for Consortium of MS Centers	2018
Recipient of Dystel Prize for research in multiple sclerosis, awarded by American Academy Of Neurology and National MS Society	2017
Recipient of Biennial prize for contribution to research in the field of neuroscience and MS Awarded by the Multiple Sclerosis Foundation of Madrid (FEMM)	2016
Elected Fellow, Academy of Medical Sciences	2015
Named lectures: ECTRIMS Lecture, the Don Paty Memorial Lecture, the Charcot Lecture	2014/15
Awarded ECTRIMS Honorary Lifetime Membership	2012
Delivered Gowers Lecture, UCL Institute of Neurology, Queen Square	2009
Awarded Doctores Honoris Causa - Honorary Doctorate, Hasselt University, Belgium	2008
B.S. Singhal Oration, Mumbai	2007
Appointed as a Guarantor of <i>Brain</i>	2005
Received Pioneer of the Nation award (awarded at Buckingham Palace)	2003

SOME APPOINTMENTS AND AFFILIATIONS

International

Chair, Scientific Advisory Committee, International Progressive MS Alliance	2012 to date
Member, Advisory Committee on Research Programs, National MS Society (USA)	2009 to date
Member of International Advisory Committee on Clinical Trials of new drugs in MS	2000 to date
Chairman of the International Medical and Scientific Board of MSIF	2005-2015
Member, WHO International Advisory Group for the revision of 'Diseases of the Nervous System' (ICD-10/ICD-11)	2009-2012

European

Member of RIMS (Rehabilitation in MS) Advisory Board	1999 to date
Chairman of the Scientific Board, MS/MRI Research Unit, Multiple Sclerosis Centre for Research and Care, Free University, Amsterdam, The Netherlands	2002 -2014
MAGNIMS (MRI in MS) - EC funded research programmes, Steering Committee	1995 - 2011

UK

Department of Health/NICE

Member of Advisory Group for Department of Health's Research Initiative for Long Term Conditions 2004 - 2010

Industry advisory panels

Chair, Eisai Clinical Neuroscience Advisory Board 2008 to date
Hoffman La Roche, PPMS/RRMS therapeutics 2017
MedDay Scientific Advisory Committee for Progressive MS 2014-2015
IMANOVA Board of Directors 2012-2014
Member, Merck Serono Advisory Group, PPMS study 2010-2012
Member, FTY720 PPMS Study Steering Committee, Novartis 2007-2011

Clinical Trial activity

Steering Committee member for the CUPID (Cannabinoid Use in Progressive Inflammatory Brain Disease) Study 2005-2012

Editorial Boards

<i>Multiple Sclerosis Journal</i> :	Editor-in-Chief	2006 to date
(Impact Factor 4.840)	European Editor	1999-2005
<i>Lancet Neurology</i>	Editorial Board	2003 to date

Reviewer of Grants for

Medical Research Council; Wellcome Trust; Department of Health; Multiple Sclerosis Society; NIHR National Institute for Health Research Invention for Innovation Programme; British Brain and Spine Foundation; NHS Research & Development Health Technology Assessment Programme; NHS Executive Research and Development Directorate; MS Ireland; Associazione Italiana Sclerosi Multipla; Istituto Superiore di Sanità, Rome; ARSEP (French Multiple Sclerosis Society), Fundació La Marató de TV3 (Agència de Qualitat i Avaluació Sanitàries de Catalunya) Barcelona, and others.

CHARITIES

NHNN Development Foundation (National Brain Appeal) Trustee	1998 to date
Worshipful Company of Pewterers, Trustee	2010-2017
MSIF (MS International Federation) Board of Directors (Chair Int Med Sci Board)	2003-2015

CURRENT GRANT AWARDS

Recent grant income covering programme and project grants and collaborations include:

- Lead on UCL bid to host UK Dementia Research Institute Hub. £250 million granted by MRC and ARUK to UCL in December 2016
- Multiple Sclerosis Society of Great Britain and Northern Ireland: £1,350,000 for 'Imaging research to facilitate new treatments for multiple sclerosis'. Joint Principal Investigator; 2013-2018
- Wellcome Trust: £389,147.00 awarded to Shift MS, Sustaining Excellence Award 'Engaging Science' for project 'Sustainable Reporters', creating a dialogue between MS patients and researchers. Project Team member, 2016-2019
- German Aerospace Center, Health Research-ERA-NET NEURON: Euros 1.08 million for 'hMRlofSCI' under NEURON call 'External Insults to the Nervous System', co-applicant, 2017-2022
- Alzheimers Research UK: £10 million to fund a Drug Discovery Institute at UCL, 2014-2019
- Takeda: £1 million to fund a Centre of Excellence in CNS Research at UCL, 2014-
- Wellcome Trust, Institutional Strategic Support Fund; £3 million to support UCL researchers of excellence; Institutional Lead, 2014 to date
- MRC: £2,100,000 for Confidence-in-Concept Scheme for translational research projects. Co-applicant; 2012 to date
- Wolfson Foundation: £20,000,000 for Leonard Wolfson Experimental Neurology Centre and associated research programme. Co-PI; 2012-2017
- Eisai Inc: £1,250,000 for research PhD Fellowships at LWENC, 2012-2017 .

ACADEMIC SUPERVISION

Supervisor for 21 successful PhDs and MDs since 1995. Currently supervising 3 PhD students

TEACHING ACTIVITY AND EXAMINATION

Teaches neurology to postgraduate students focusing on the diagnosis and management of disability, particularly multiple sclerosis, on neurorehabilitation, outcome measurement, and MRI.

Frequently invited to deliver lectures internationally.

Examiner for PhD and MD theses in UK and internationally.

RESEARCH SUMMARY

Current focus:

- Diagnosis, evaluation, and management of the progressive forms of multiple sclerosis. Chair of the Scientific Advisory Committee for the International Progressive MS Alliance.
- Applying new imaging techniques to explore acute spinal cord injury in collaboration with UCL/Zurich University team

Research background:

(1) Understanding the pathological mechanisms that underpin neurological disability and recovery using structural and functional imaging - developed new MRI techniques including tractography, providing insights into structural damage in MS, ALS and stroke; evaluated patterns of recovery using functional MRI in MS and stroke.

(2) Developed and evaluated scientifically sound outcome measures that incorporate the patient's perspective. Developed, with colleagues, new outcome measures in MS (MS Impact Scale, MS Walking Scale) for spasticity, cervical dystonia, ataxia and pain.

(3) Characterised MRI findings in primary progressive MS; developed first diagnostic criteria for this patient group.

(4) Led the first studies of beta-interferon in primary and secondary progressive MS.

(5) Carried out RCTs of neurological rehabilitation and community-based treatment of relapses in MS.

(6) Evaluated the role of cannabinoids in the treatment of spasticity in MS and role as a neuroprotective agent.

(7) Developed standards of care for MS in 1998, incorporated into the NICE guidance for MS and the NSF for Long-Term Neurological Conditions.

(8) Increasing engagement and improved communications for persons with MS; with Shift MS.

As Dean of the Faculty of Brain Sciences, leads comprehensive programmes of research in dementia and mental health and led successful bid for Hub of UK Dementia Research Institute (£250 million). As Neuroscience lead for *UCL Partners* has jointly led innovation in treatment pathways for stroke and brain cancer.

PUBLICATIONS

H-index of 108. Over 500 research and other articles have been published in peer-reviewed journals, with over 45,548 citations - including paper on diagnostic criteria for MS (McDonald et al, *Annals of Neurology* 2001;50:121-127) - 4356 citations; 2005 revision - 3194 citations; 2011 revision (Polman et al, *Annals of Neurology* 2011;69:292-302) - 2921 citations. An ISI highly cited researcher for Neuroscience, 257 out of 6061 highly-cited scientists on Essential Science Indicators for Neuroscience and Behavior. Authored 17 books and 41 chapters. Researcher ID profile: <http://www.researcherid.com> Researcher ID C-2654-2008

TOP PUBLICATIONS

1. Thompson AJ, Banwell BL, Barkhoff FCohen J. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurology* 2018; 17:162-173. Impact Factor: 23.468
2. Montalban X, Gold R, Thompson AJ et al.ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. *Multiple Sclerosis Journal*, published online 20 January 2018; *European Journal of Neurology* 2018; 25:215-237
3. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple Sclerosis. Seminar. *The Lancet* 2018; 391:1623-36. Impact Factor: 47.831
4. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Soelberg Sorensen P, Thompson AJ et al. Defining the course of multiple sclerosis. The 2013 revisions. *Neurology* 2014; 83:278-286. Impact Factor: 8.166
5. Freund P, Weiskopf N, Ashburner J, Wolf K, Sutter R, Altmann DR, Friston K, Thompson A, Curt A. MRI investigation of the sensorimotor cortex and corticospinal tract after acute spinal cord injury: a prospective longitudinal study. *Lancet Neurology* 2013;12(9):873-881. Impact Factor: 23.468
6. Ciccarelli O, Thomas D, De Vita E, Wheeler-Kingshott CAM, Kachramanoglou C, Kapoor R, Leary S, Matthews L, Palace J, Chard D, Miller D, Toosy A, Thompson A. Low myo-inositol indicating astrocytic damage in a case series of NMO. *Annals of Neurology* 2013; 74(2):301-305. Impact Factor: 9.638
7. Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, Du M-Q, Luan S-L, Altmann DR, Thompson AJ, Compston A, Scott MA, Miller DH, Chandran S. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. *Lancet Neurology* 2012; 11:150-156. Impact Factor: 23.468
8. Freund P, Weiskopf N, Ward NS, Hutton C, Gall A, Ciccarelli O, Craggs M, Friston K, Thompson AJ. Disability, atrophy and cortical reorganization following spinal cord injury. *Brain* 2011; 134:1610-1622. Impact Factor: 10.103
9. Polman CH, Reingold SC, Banwell B, (...) Thompson AJ, (...) Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria. *Annals of Neurology* 2011; 69:292-302. Impact Factor: 9.638
10. Jenkins TM, Toosy AT, Ciccarelli O, Miszkiel KA, Wheeler-Kingshott CA, Henderson AP, Kallis C, Mancini L, Plant GT, Miller DH, Thompson AJ. Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. *Annals of Neurology* 2010;67:99-113. Impact Factor: 9.638
11. Khaleeli Z, Ciccarelli O, Manfredonia F, Barkhof F, Brochet B, Cercignani M, Dousset V, Filippi M, Montalban X, Polman C, Rovaris M, Rovira A, Sastre-Garriga J, Vellinga M, Miller D, Thompson A. Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. *Annals of Neurology* 2008;63:790-793. Impact Factor: 9.638
12. Ciccarelli O, Wheeler-Kingshott CA, McLean MA, Cercignani M, Wimpey K, Miller DH, Thompson AJ. Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. *Brain* 2007; 130:2220-2231. Impact Factor: 10.103
13. Toosy AT, Hickman SJ, Miszkiel KA, Jones SJ, Plant GT, Altmann DR, Barker GJ, Miller DH, Thompson AJ. Adaptive cortical plasticity in higher visual areas after acute optic neuritis. *Annals of Neurology* 2005;57:622-633. Impact Factor: 9.638
14. Hobart JC, Lamping DL, Fitzpatrick R, Riazi A, Thompson AJ. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. *Brain* 2001;124:962-973. Impact Factor 9.977
15. Hobart JC, Cano SJ, Zajicek JP, Thompson AJ. Rating scales as outcome measures for clinical trials in neurology: problems, solutions and recommendations. *Lancet Neurology* 2007;6:1094-105. Impact Factor: 23.468